LEGN250117C30000
- 3.50
- 0.000.00%
Legend Biotech Newsroom
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $84
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Promising Growth Trajectory and Market Expansion Justify Buy Rating for Legend Biotech
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating
Legend Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)
Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $78
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $65 to $91
Optimistic Buy Rating for Legend Biotech Driven by Carvykti's Success and Growth Potential
William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $83
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
Analysts Conflicted on These Healthcare Names: NeueHealth Inc (NEUE), Agilent (A) and Legend Biotech (LEGN)
Legend Biotech (LEGN) Gets a Buy From RBC Capital
Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $82
Morgan Stanley Remains a Buy on Legend Biotech (LEGN)
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating